Compare Abbott Laboratories (ABT) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Liberty Global Ltd Class C — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Liberty Global Ltd Class C trades at $10.4 (market cap $3.60B). The key difference: Abbott Laboratories is far larger — about 46.4× Liberty Global Ltd Class C's market cap, and Abbott Laboratories pays a 2.63% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| ABT | LBTYK | |
|---|---|---|
Market Cap | $166.94B | $3.60B |
Sector | Health | Technology |
52-Week High | $136.62 | $12.67 |
52-Week Low | $82.57 | $10.07 |
Enterprise Value | $193.69B | $10.89B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
LBTYK trades at $10.50, down 3.67% today, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $7.14B in 2025 despite $4.88B revenue, though recent Q1 2026 earnings beat expectations. Analyst sentiment remains positive with 69% buy ratings, while technical indicators show resistance at $11 and support at $10.
The outlook hinges on the planned 2027 Ziggo Group spin-off, which could unlock value, but persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. Near-term catalysts include Q2 2026 results in July, with the stock offering speculative upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
